Shingles

Results support a 2020 meta-analysis showing that older adults with chronic pain are nearly twice as likely to develop frailty compared to those without chronic pain.

Antiviral treatments can accelerate healing and reduce complications.

Researchers recommend early vaccination against herpes zoster to mitigate the risks.

Short-term spinal cord stimulation could provide long-term pain relief and improve the overall quality of life for individuals with herpes zoster-associated pain and postherpetic neuralgia.

Varicella-zoster vaccination could prevent fatal outcome among individuals with disseminated herpes zoster.

The findings suggest that VZV is a common cause of CNS infections, even when there is no visible rash.

During a 15-year period, 1 in 5 older adults living with COPD received a shingles vaccine.

Although shingles is more common in adults, children who have had chickenpox or the chickenpox vaccine can develop shingles.

An increase of shingles vaccination was reported among individuals with asthma.

Pharmacists can continue to spread awareness of the importance of receiving a shingles vaccine.

Use of antitherapeutic medication prescribed for herpes zoster related to lower risk of subsequent dementia.

Brivudine is more effective in treating herpes zoster and does not increase the risk of adverse reactions.

Treatment with valacyclovir for a year decreased the risk of new or worsening eye disease by 26%.

The results emphasize the need for pharmacists and health care providers to further educate patients about receiving recommended immunizations.

Female and older patients had a greater incidence of herpes zoster ophthalmicus and were more likely to develop ocular complications.

The Inflation Reduction Act's zero cost-sharing policy resulted in significant increases in shingles vaccines dispensed to individuals under Part D, compared with those who are commercially insured.

Currently, the CDC recommends the recombinant zoster vaccine (Shingrix, RZV; GSK) for the prevention of herpes zoster and related complications.

Dermatomal reactions could occur following recombinant zoster vaccine to treat shingles.

Immediate-early 62 enclosed inside small extracellular vesicles can transport from the site of infection, causing it to penetrate cells and shut down their antiviral response.

Individuals with a history of shingles was significantly and independently connected with a 20% higher risk of for subjective cognitive decline.

The findings indicate that zoster vaccine recombinant reduced dementia risk by 17% in an analysis of over 200,000 patients.

The recombinant zoster vaccine demonstrated a 79.7% efficacy in patients aged 50 years and older cumulatively within the 6- to 11-year period after vaccination.

In a recent study, approximately 99% of children who received solid organ transplant and live vaccination against rubella had antibodies 1 to 3 months post-vaccination.

Moderna has advanced 6 programs into late-stage development, including for respiratory conditions, latent and other viruses, oncology, and rare diseases.

Vaccination is especially important for older adults with any chronic health conditions because vaccines can prevent serious illness and resulting complications down the road.

It is possible that the pandemic had a positive impact on influenza vaccination rates.

Staff members, especially immunizers, should look at every encounter as an opportunity to educate, support patients.

Due to the success of mRNA technology with COVID-19, there has been a significant increase in research looking into utilizing mRNA technology, and more specifically, how it can help to advance vaccine development.

Case studies highlight questions about shingles.

Letermovir is the only drug approved for prophylaxis of cytomegalovirus (CMV) infection for patients who are CMV-seropositive and have received an allogeneic HSCT.